Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine

A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve the problems of non-specificity and difficult side effects

Inactive Publication Date: 2018-06-29
天津亨佳生物科技发展有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DCs induced by tumor-associated high-expression proteins are not strictly specific, and tissue cells other than tumors also express the same protein, so its side effects are a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine
  • Antigen peptide chain group for treating tumor and application of antigen peptide chain group in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Patient A, female, 51 years old. Lung adenocarcinoma, clinical stage IV, progressed after 5 cycles of pemetrexed combined with cisplatin chemotherapy. Multiple metastases in the lungs. A biopsy of the lung lesion was taken, and 488 tumor occurrence and development-related gene panels and HLA typing chips were detected. The patient carried the EGFR 19DEL mutation, and the HLA typing was HLA-A: A*1001A*3103; HLA-B: B* 3101B*4016; HLA-C: C*0303C*0802; HLA-DQB1: DQB1*0302DQB1*0202; HLA-DRB1: DRB1*0405DRB1*1201.

[0070] Use the specific tumor antigen peptide chain combination therapy of the present invention once a week for a total of 6 weeks. Detect the secretion of specific CD8+Tetramer+T cells by spot detection before and after the injection of antigen peptide chain group (hereinafter referred to as "medication"), and observe the changes in tumor size 6 weeks before and after the administration by imaging. The results are as follows: figure 1 and figure 2 shown. Th...

Embodiment 2

[0075] Patient B, male, 58 years old, developed left lung adenocarcinoma after 5 cycles of chemotherapy and oral molecular targeted drug gefitinib. Lung tumor biopsy was performed, and 488 tumor occurrence and development-related gene panels and HLA typing chips were detected: the patient carried the EGFR 19DEL mutation. HLA typing is HLA-A: A*0301A*3304; HLA-B: B*1801B*4002; HLA-C: C*0601C*0401:; HLA-DQB1: DQB1*0202DQB1*0201; HLA-DRB1: DRB1 *0401DRB1*1004.

[0076] Combination therapy was performed with the antigen peptide chain group for treating tumors of the present invention once a week for a total of 12 weeks. The specifically selected peptide chain is as follows: SEQ ID No: 4+SEQ ID No: 6+SEQ ID No: 11+SEQ ID No: 14+SEQ ID No: 16+SEQ ID No: 33.

[0077] The changes in the size of lung tumors before and after treatment are as follows: image 3 shown by image 3 It can be seen that before drug treatment, the size of the right lung tumor was 4cm×5cm ( image 3 -A); Af...

Embodiment 3-60

[0079] Example 3-60 Cancer patients of different types and degrees were taken, and 488 tumor occurrence and development-related gene panels and HLA typing chip tests were performed. All patients were patients with EGFR 19DEL mutations, and different antigen peptide chain groups were used. The combined form of treatment was given once a week for 12 weeks. The results of HLA*A3101-HVKITDFGR Tetramer staining and the change of lung tumor size before and after treatment in Example 3-60 are similar to those in Example 1-2, and will not be repeated here due to space limitations. The above results can all show that the antigen peptide chain group of the present invention can induce dendritic cells that produce tumors, and dendritic cells as antigen-presenting cells can present antigen information to T cells, interact with T cells, and cause T cells to produce tumors. It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.

[0080] During th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigen peptide chain group for individual immuno-biological treatment on tumor, and the application of the antigen peptide chain group in medicines. The antigen peptide chain group for treating tumor comprises any one or a combination of at least two amino acid sequences of SEQ ID No:1-34 as shown in the specification. The antigen peptide chain group disclosed by the invention is capable of inducing dendritic cells for resulting tumor, so that the dendritic cells as antigen presenting cells are capable of representing antigen information to T cells and interact withthe T cells, then cells for specifically killing tumor can be generated from the T cells, and a function of killing tumor cells can be achieved.

Description

technical field [0001] The invention belongs to the technical field of malignant tumor bioimmune drugs, and in particular relates to an antigen peptide chain group for individualized biological immunotherapy of tumors and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is increasing, the mortality rate is high, and the prognosis is poor. The National Cancer Prevention and Research Office of the National Cancer Center released the largest comprehensive analysis of cancer survival data in China in the International Journal of Cancer. The data shows that the 5-year survival rate of cancer in China is 30.9%, which is far lower than that of developed countries; at the same time, the survival rate of rural patients is only half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, cancers such as lung cancer, gastric cancer, and liver cancer are more common, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08C07K19/00A61K38/08A61K38/10A61P35/00
CPCC07K7/06A61K38/00C07K7/08C07K2319/00
Inventor 刘玉强霍冲孙旭东
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com